医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

FPT Software Renews HITRUST r2 Certification, Upholding The Highest Standards Of Security And Compliance

2024年05月15日 PM06:20
このエントリーをはてなブックマークに追加


 

HANOI, Vietnam

FPT Software, a leading global IT company, has earned HITRUST Risk-based, 2-year (r2) Certification for its Web Services System, Database System and Deployment System. This marks the second consecutive time that FPT Software achieved this recognition, underscoring its ongoing commitment to the highest standards of data protection and risk management.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240514108070/en/

HITRUST Risk-Based, 2-year (r2) Certification validates FPT Software is committed to strong cybersecurity and protecting sensitive data. (Graphic: Business Wire)

HITRUST Risk-Based, 2-year (r2) Certification validates FPT Software is committed to strong cybersecurity and protecting sensitive data. (Graphic: Business Wire)

HITRUST Risk-based, 2-year (r2) Certification demonstrates that FPT Software’s systems have met demanding regulatory compliance and industry-defined requirements and are appropriately managing risk. By including federal and state regulations, standards, and frameworks and incorporating a risk-based approach, the HITRUST Assurance Program helps organizations address security and data protection challenges through a comprehensive and flexible framework of prescriptive and scalable security controls.

The HITRUST Certification offers FPT Software’s existing clients enhanced assurances of security and a competitive edge in their operations. For potential clients, this validation positions FPT Software as a reliable choice in the competitive healthcare sector, showcasing our dedication to stringent security measures and adherence to best practices.

“This continuous achievement of HITRUST r2 certification demonstrates our capacity to meet and exceed the stringent demands of world-class healthcare data privacy, cybersecurity, and risk management standards,” said Chu Canh Chieu, Head of Global Healthcare Solutions, FPT Software. “Healthcare is our primary industry focus. FPT Software is committed to innovating alongside our partners to create a more connected, secure, and efficient healthcare ecosystem.”

“Achieving HITRUST certification places FPT Software among an elite group of global organizations. This certification is renowned as the gold standard due to its comprehensive control requirements, thorough assurance process, and rigorous oversight ensuring accuracy and reliability,” said Jeremy Huval, Chief Innovation Officer at HITRUST.

FPT Software received the HITRUST Risk-based, 2-year (r2) Certification for the first time in 2022. With over 15 years of experience in this sector, the company has been a trusted partner of more than 50 medical institutions worldwide, notably IHH Healthcare, BrightInsight, and MedAdvisor.

About FPT Software

FPT Software, a subsidiary of FPT Corporation, is a global technology and IT services provider headquartered in Vietnam, with $1 billion in revenue (2023) and over 30,000 employees in 30 countries.

The company champions complex business opportunities and challenges with its world-class services in Advanced Analytics, AI, Digital Platforms, Cloud, Hyperautomation, IoT, Low-code, and so on. It has partnered with over 1,000+ clients worldwide, 91 of which are Fortune Global 500 companies in Aviation, Automotive, Banking, Financial Services and Insurance, Healthcare, Logistics, Manufacturing, Utilities, and more. For more information, please visit https://fptsoftware.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20240514108070/en/

CONTACT

Media contact

Mai Duong (Ms.)

FPT Software

PR Manager

MCP.PR@fpt.com

同じカテゴリーの記事 

  • Heuron Gets FDA Green Light for Stroke Triage and Notification Solution
  • iCell Gene Therapeutics Announces Positive Clinical Data from Investigator Initiated Phase 1 Trial Evaluating BCMA-CD19 Compound CAR in Patients with Systemic Lupus Erythematosus/Lupus Nephritis Published in Annals of the Rheumatic Diseases
  • Galderma Launches Restylane® VOLYME™ in China – One of the World’s Fastest Growing Aesthetics Markets
  • Immunis Partners with Japanese Drug Company Toray to Reverse Sarcopenia
  • Otsuka to Terminate Development of AVP-786